{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"LIMBER","nct_id":"NCT04279847","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=limber-nct04279847. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LIMBER","arms":[{"description":"INCB057643 dose escalation and dose expansion","label":"Part 1 : INCB057643 Monotherapy","type":"EXPERIMENTAL"},{"description":"Combination arm in dose escalation and dose expansion","label":"Part 2 : INCB057643 Combination with Ruxolitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"conditions":["Myelofibrosis","Myelodysplastic Syndrome","Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome","Myeloproliferative Neoplasm","Relapsed or Refractory Primary Myelofibrosis","Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)","ET (Essential Thrombocythemia)"],"enrollment":{"count":140,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"INCB057643","otherNames":[],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-01","lead_sponsor":"Incyte Corporation","official_title":"A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of treatment-emergent adverse events","timeFrame":"Up to approximately 9 months"}],"references":[],"start_date":{"date":"2021-02-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","url":"https://clinicaltrials.gov/study/NCT04279847"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/limber-nct04279847"}